Advertisement

Topics

Companies Related to "Factor Thrombin Inhibitors Pipeline Insights 2017 Updated 30052017" [Most Relevant Company Matches] RSS

19:57 EDT 23rd June 2018 | BioPortfolio

Here are the most relevant search results for "Factor Thrombin Inhibitors Pipeline Insights 2017 Updated 30052017" found in our extensive corporate database of over 50,000 company records.

Showing "Factor Thrombin Inhibitors Pipeline Insights 2017 Updated 30052017" Companies 1–25 of 1,600+

Relevant

Nuvelo

Nuvelo, Inc. is a publicly traded biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes several acute cardiovascular and oncology programs. The cardiovascular portfolio includes three programs: alfimeprase, a direct acting thr...


Synapse BV

Synapse BV is a working group within the Cardiovascular Research Institute Maastricht (CARIM) as well as a company within the Maastricht University Holding. It carries out developmental research in the field of the (patho-)physiology of haemostasis and thrombosis, operating in the niche between biochemistry and molecular biology on the one side and pharmaceutical- and clinical sciences on the othe...

Globe Laboratories

Globe Labs manufactures and sells high quality, low cost human therapeutic proteins, human growth hormones, enzymes, research laboratory cytokines, chemokines & their respective inhibitors/antagonists for research and veterinary use. We are also manufacturers of bulk quantities for other pharmaceutical companies worldwide. Globe Labs is proud to have the largest antagonist product list in the worl...


KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...

Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer...

Fit Factor Network, Inc.

Fit Factor Network, Inc. was founded by Hillsborough County physical education teacher, Scott Owen, for the purpose of improving the health of children and families. The company produces the Fit Factor Kids DVD - a 45 minute exercise DVD developed for and hosted by kids. The DVD is comprised of six workouts and three educational Fit Tip segments. For additional information, visit www.FitFactorKids...

Amura Holdings Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™:An Osteoporosis programme based on cathepsin K inhibitors, A Psoriasis programme based on a cathepsin S inhibit...

Accredo Nova Factor

For more than 20 years, Accredo Nova Factor has provided nationwide distribution and pharmaceutical care management for the biopharmaceutical industry. Accredo Nova Factor currently has 15 product lines that are dispensed from its specialty pharmacy headquarters in Memphis, Tenn. The products are usually shipped overnight to the patients' homes, where patients are trained to reconstitute and self-...

Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq: HNAB) is a biopharmaceutical company dedicated to developing new, differentiated cancer therapies designed to improve and enable current standards of care. The Company has two lead product candidates that target large markets and are in pivotal and/or proof-of-concept clinical trials. Marqibo(R) is being developed to treat lymphoid cancers such as ALL and lymph...

Nuvelo, Inc.

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical proce...

Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Prote...

BIOPUR AG

BIOPUR manufactures highly purified proteins and enzymes derived from human and animal sources for research use. Our focus is the extraction of proteins and enzymes from native plasma and other sources. We also offer customized purification of very rare proteins in larger quantities. Some examples of our product line are coagulation factors like Thrombin, extra-cellular-martix (ECM) proteins for c...

BTI

BTI has been manufacturing growth factor (GF) and attachment factor (AF) products since 1981. Our extensive product line includes receptor-grade, aseptically packaged GFs and AFs. These are highly purified proteins that have been membrane filtered, aseptically filled and lyophilized. Most BTI GFs have been tested in cell culture, receptor binding studies and in immunoassays. Some GFs are availa...

ILEX Oncology

Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ILEX is also advancing a robust pipeline of oncology product candidates. The pipeline comprises multiple technologies at all stages of clinical development, including a monoclonal antibody, apoptosis-inducing agents, cytotoxic compounds with novel mechanisms o...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Genomic Discovery Tools, U.S.

TransFind is a tool for the identification of potential transcription factor complexes several genes in a genelist have in common. TransFind can be used for searching transcription factor binding sites results from MEME , GIBBS , & TESS visually. Transfind can also be used to create an oligonucleotide decoy for a transcription factor of interest and move forward in RNAi target selection. Recent us...

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergar...

Q Factor

Q Factor radically improves user experiences over today’s increasingly congested wireless networks by streamlining the distribution of content. As the world becomes more unwired, users still expect their browsing or viewing experiences on any device, in any location, to be consistent, uninterrupted and high quality. For this to happen, a lot of complex ...

NAM Asia Hong Kong Co., Ltd.

CEO Teppei Nakano graduated from Keio University School of Medicine in 2017. We have been adopting IPA unexplored projects by the Ministry of Economy, Trade and Industry, which represent a large number of representatives of IT companies representing Japan, twice in 2016 and 2017, independent businesses that have been adopted by unexplored This is the NAM p...

QIAGEN GmbH

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Capitol Insights

Capitol Insights helps organizations develop and implement comprehensive public relations and government affairs programs to educate the public, motivate people and shape public policy.Capitol Insights helps clients understand how policy may move in the future because of changes in public opinion, political pressure and legal interpretation. Helping organizations make better decisions and build st...

Isarna Therapeutics GmbH

Isarna Therapeutics has an unmatched commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. Isarna Therapeutics are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.  The role of tgf-beta in cancer The cytokine human transforming growth ...

QIAGEN N.V.

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Transcend Insights and Humana Inc.

Transcend Insights, the population health technology company of Humana Inc. (NYSE: HUM), provides solutions that rise above data silos and connect care teams with the insights they need to succeed in a value-based care world. By leveraging its leading-edge approach to data aggregation, interoperability and analytics, Transcend Insights provides health syst...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...


More From BioPortfolio on "Factor Thrombin Inhibitors Pipeline Insights 2017 Updated 30052017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks